Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2009 2
2012 1
2013 2
2014 7
2015 1
2016 3
2017 2
2018 1
2019 1
2020 2
2021 4
2022 5
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean gaetano rinaldi (2 results)?
Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program.
Quaglino P, Ascierto PA, Consoli F, Queirolo P, Spagnolo F, Morelli MF, Berardi R, Chiarion-Sileni V, Tucci M, Troiani T, Melotti B, Rossi E, Mandala M, Rinaldi G, Marcon IG, Pizzuti M, Del Vecchio M. Quaglino P, et al. Among authors: rinaldi g. Cancer Manag Res. 2023 Nov 11;15:1271-1281. doi: 10.2147/CMAR.S423970. eCollection 2023. Cancer Manag Res. 2023. PMID: 38027240 Free PMC article.
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile.
Ascierto PA, Di Giacomo AM, Chiarion Sileni V, Queirolo P, Spagnolo F, De Galitiis F, Cognetti F, Mandalà M, Guidoboni M, Rinaldi G, Depenni R, Consoli F, Troiani T, Guida M, Marconcini R, Ferrucci PF, Strippoli S, Fava P, Merelli B, Simeone E, Di Guardo L, Giannarelli D, Maio M, Quaglino P, Del Vecchio M. Ascierto PA, et al. Among authors: rinaldi g. Eur J Cancer. 2023 Sep;191:113246. doi: 10.1016/j.ejca.2023.113246. Epub 2023 Jul 19. Eur J Cancer. 2023. PMID: 37549531
Outcomes in patients with BRAFV600-mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib.
Aglietta M, Chiarion-Sileni V, Fava P, Guidoboni M, Depenni R, Minisini A, Consoli F, Ascierto PA, Rinaldi G, Banzi M, Marconcini R, Gueli R, Ferraresi V, Tucci M, Tonini G, Lo Re G, Guida M, Del Vecchio M, Marcon IG, Queirolo P. Aglietta M, et al. Among authors: rinaldi g. Tumori. 2023 Dec;109(6):537-545. doi: 10.1177/03008916231179251. Epub 2023 Jul 7. Tumori. 2023. PMID: 37417313 Free PMC article.
Clinical, histopathological and molecular features of dedifferentiated melanomas: An EORTC Melanoma Group Retrospective Analysis.
Hench J, Mihic-Probst D, Agaimy A, Frank S, Meyer P, Hultschig C, Simi S, Alos L, Balamurugan T, Blokx W, Bosisio F, Cappellesso R, Griewank K, Hadaschik E, van Kempen LC, Kempf W, Lentini M, Mazzucchelli L, Rinaldi G, Rutkowski P, Schadendorf D, Schilling B, Szumera-Cieckiewicz A, van den Oord J, Mandalà M, Massi D; EORTC Melanoma Group. Hench J, et al. Among authors: rinaldi g. Eur J Cancer. 2023 Jul;187:7-14. doi: 10.1016/j.ejca.2023.03.032. Epub 2023 Apr 2. Eur J Cancer. 2023. PMID: 37098294 Free article.
The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study.
Del Vecchio M, Chiarion Sileni V, Quaglino P, Rinaldi G, Minisini A, Troiani T, Consoli F, Sponghini A, Banzi M, Morelli MF, Palleschi D, Rossi E, Marconcini R, Depenni R, Carnevale-Schianca F, Marcon I, Queirolo P. Del Vecchio M, et al. Among authors: rinaldi g. Cancers (Basel). 2023 Mar 26;15(7):1980. doi: 10.3390/cancers15071980. Cancers (Basel). 2023. PMID: 37046641 Free PMC article.
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay.
Incorvaia L, Rinaldi G, Badalamenti G, Cucinella A, Brando C, Madonia G, Fiorino A, Pipitone A, Perez A, Li Pomi F, Galvano A, Gristina V, Barraco N, Bono M, Bazan Russo TD, Toia F, Cordova A, Fanale D, Russo A, Bazan V. Incorvaia L, et al. Among authors: rinaldi g. Ther Adv Med Oncol. 2023 Feb 15;15:17588359231151845. doi: 10.1177/17588359231151845. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36818688 Free PMC article.
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer.
Cavalieri S, Serafini MS, Carenzo A, Canevari S, Lenoci D, Pistore F, Miceli R, Vecchio S, Ferrari D, Moro C, Sponghini A, Caldara A, Rocca MC, Secondino S, Moretti G, Denaro N, Caponigro F, Vaccher E, Rinaldi G, Ferraù F, Bossi P, Licitra L, De Cecco L. Cavalieri S, et al. Among authors: rinaldi g. Cells. 2022 Oct 10;11(19):3176. doi: 10.3390/cells11193176. Cells. 2022. PMID: 36231138 Free PMC article.
Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2- Advanced Breast Cancer Patients: An Italian Managed Access Program.
Staropoli N, Geuna E, Rinaldi G, Bisagni G, Scotti V, Faggioni G, Vannini L, Arcara C, Moretti G, Gunnellini M, Coltelli L, Verderame F, Livi L, Sanna G, Grasso D, Abbinante G, Ragni F. Staropoli N, et al. Among authors: rinaldi g. Curr Oncol. 2022 Sep 17;29(9):6635-6641. doi: 10.3390/curroncol29090521. Curr Oncol. 2022. PMID: 36135090 Free PMC article.
37 results